Clopidogrel/aspirin - Yuhan

Drug Profile

Clopidogrel/aspirin - Yuhan

Alternative Names: Aspirin/clopidogel - Yuhan; YH 14659

Latest Information Update: 12 May 2016

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Yuhan
  • Class Antiplatelets; Antipyretics; Pyridines; Salicylic acids; Small molecules; Thienopyridines
  • Mechanism of Action Cyclooxygenase inhibitors; Nitric oxide stimulants; Platelet aggregation inhibitors; Purinergic P2 receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Discontinued Coronary disorders

Most Recent Events

  • 01 Apr 2012 Yuhan Corporation completes a Phase I trial for Coronary disorders (in healthy volunteers) in South Korea (NCT01657071)
  • 01 Mar 2012 Yuhan Corporation initiates enrolment in a Phase-I trial for Coronary disorders (in healthy volunteers) in South Korea
  • 31 Dec 2011 Yuhan completes a Phase-I trial in healthy volunteers in South Korea (NCT01422109)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top